- Home
- ENGN vs AMRN Comparison
ENGN vs AMRN Comparison
Compare ENGN & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENGN
- AMRN
- Stock Information
- Founded
- ENGN 1999
- AMRN 1989
- Country
- ENGN Canada
- AMRN Ireland
- Employees
- ENGN N/A
- AMRN N/A
- Industry
- ENGN
- AMRN Biotechnology: Pharmaceutical Preparations
- Sector
- ENGN
- AMRN Health Care
- Exchange
- ENGN Nasdaq
- AMRN Nasdaq
- Market Cap
- ENGN 204.3M
- AMRN 216.0M
- IPO Year
- ENGN N/A
- AMRN 1993
- Fundamental
- Price
- ENGN $3.62
- AMRN $16.81
- Analyst Decision
- ENGN Buy
- AMRN Strong Sell
- Analyst Count
- ENGN 7
- AMRN 1
- Target Price
- ENGN $23.29
- AMRN $12.00
- AVG Volume (30 Days)
- ENGN 93.9K
- AMRN 183.4K
- Earning Date
- ENGN 06-12-2025
- AMRN 07-30-2025
- Dividend Yield
- ENGN N/A
- AMRN N/A
- EPS Growth
- ENGN N/A
- AMRN N/A
- EPS
- ENGN N/A
- AMRN N/A
- Revenue
- ENGN N/A
- AMRN $214,112,000.00
- Revenue This Year
- ENGN N/A
- AMRN N/A
- Revenue Next Year
- ENGN N/A
- AMRN $7.88
- P/E Ratio
- ENGN N/A
- AMRN N/A
- Revenue Growth
- ENGN N/A
- AMRN N/A
- 52 Week Low
- ENGN $2.65
- AMRN $7.08
- 52 Week High
- ENGN $11.00
- AMRN $17.18
- Technical
- Relative Strength Index (RSI)
- ENGN 53.03
- AMRN 76.05
- Support Level
- ENGN $2.95
- AMRN $15.34
- Resistance Level
- ENGN $3.44
- AMRN $17.18
- Average True Range (ATR)
- ENGN 0.27
- AMRN 1.10
- MACD
- ENGN 0.06
- AMRN 0.28
- Stochastic Oscillator
- ENGN 92.31
- AMRN 92.42
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.